Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2026-03-02 Declaration of Voting R…
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement regarding the results of an Extraordinary General Meeting (EGM) held by Faron Pharmaceuticals. It details the specific voting outcome, which was the approval of a rights offering and the authorization of the Board to issue new shares. While it mentions share issuance, the primary purpose of the document is to report the results of the shareholder meeting, making it a Declaration of Voting Results (DVA).
2026-03-02 English
Faron and City of Hope in process of developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS
Regulatory Filings Classification · 98% confidence The document is a press release issued by Faron Pharmaceuticals regarding the development of a Phase II investigator-initiated clinical trial. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a corporate governance or shareholder meeting document. As it is a general regulatory announcement distributed via a news service (MFN) regarding company operations and clinical trial progress, it falls under the 'Regulatory Filings' (RNS) category.
2026-03-02 English
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
Regulatory Filings Classification · 98% confidence The document is a press release from Faron Pharmaceuticals announcing that clinical trial data for their drug 'bexmarilimab' has been accepted for a poster presentation at an upcoming scientific meeting (BSH 2026). It does not contain full financial statements, nor is it a mandatory regulatory filing for a specific financial period. It functions as a general corporate announcement regarding research and development progress. As it does not fit into specific categories like 'Earnings Release' or 'Investor Presentation' (which usually contain detailed financial slides), it falls under the 'Regulatory Filings' (RNS) category as a general corporate news announcement distributed via a regulatory news service.
2026-02-23 English
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML
Regulatory Filings Classification · 98% confidence The document is a press release issued by Faron Pharmaceuticals announcing the initiation of a Phase II clinical trial (BEAM-X). It provides details on the trial's purpose, the drug candidate (bexmarilimab), and the collaboration with the Nordic AML Group. As it is a corporate announcement regarding business operations and clinical development, and does not fit into specific financial reporting categories like 10-K or IR, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general regulatory announcements distributed via news services.
2026-02-19 English
Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice to the Extraordinary General Meeting' (EGM) issued by Faron Pharmaceuticals. It outlines the agenda for the upcoming meeting, including a proposal to authorize the Board to resolve on a rights offering. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting details, agenda items, and voting procedures. It fits the definition of a Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to participate and vote.
2026-02-09 English
Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones
Capital/Financing Update Classification · 100% confidence The document is a formal company announcement from Faron Pharmaceuticals regarding a planned rights offering of approximately EUR 40 million to raise capital. It details the purpose of the offering (funding clinical trials for bexmarilimab), the intent to convene an Extraordinary General Meeting (EGM) for shareholder approval, and the appointment of a financial coordinator. This falls under the category of capital raising and financing activities.
2026-02-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.